-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Non-Small Cell Lung Cancer Drug Details: FPI-2068...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Pancreatic Ductal Adenocarcinoma Drug Details: FPI-2068 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Metastatic Colorectal Cancer Drug Details: FPI-2068 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-1434 in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-1434 in Ewing Sarcoma Drug Details: FP1-1434 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-1434 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-1434 in Solid Tumor Drug Details: FP1-1434 is under development for...
-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Although the pharmaceutical industry is often labeled as a recession-resistant, it is not immune to future challenges. Ongoing issues such as constraints on drug pricing and reimbursement (P&R), the evolving regulatory landscape, pressures to innovate, and pressures to address environmental, social, and governance (ESG) issues will continue to pose challenges for the pharmaceutical sector in the coming years. In this “The State of the Biopharmaceutical Industry” report, GlobalData examines the business environment and trends that are going to shape the...
-
Product Insights
Net Present Value Model: Actinium Pharmaceuticals Inc’s Actimab-A
Empower your strategies with our Net Present Value Model: Actinium Pharmaceuticals Inc's Actimab-A report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabatolimab in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabatolimab in Myelofibrosis Drug Details: Sabatolimab is under development for the treatment of...